Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis

Retina

Volumn 33, Issue 8, 2013, Pages 1684-1693

  Burkholder, Bryn M ^a   Wang, Jiangxia ^b   Dunn, James P ^a   Nguyen, Quan D ^a   Thorne, Jennifer E ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Departments of Epidemiology   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

birdshot chorioretinitis; fluocinolone acetonide implant; posterior uveitis

Indexed keywords

FLUOCINOLONE ACETONIDE; IMMUNOMODULATING AGENT;

ADULT; AGED; ARTICLE; BIRDSHOT CHORIORETINITIS; CHORIORETINITIS; CLINICAL ARTICLE; DRUG DELIVERY DEVICE; FEMALE; GLAUCOMA SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPLANT; INFLAMMATION; INTRAOCULAR PRESSURE; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RETINA MACULA CYSTOID EDEMA; UVEITIS; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; CHORIORETINITIS; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PANUVEITIS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS, POSTERIOR; VISUAL ACUITY;

EID: 84883741198     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31828396cf     Document Type: Article

References (42)

1. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000;107:2024-2033.
2. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirtyfour-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027.
3. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-3575.
4. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-1201.
5. Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117:567-575, 575 e1.
6. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916-1926.
7. Seth RK, Gaudio PA. Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm 2008;16:103-105.
8. Mahajan VB, Gehrs KM, Goldstein DA, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology 2009;116:552-557 e1.
9. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-1485.
10. Bollinger K, Kim J, Lowder CY, et al. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology 2011.
11. Thorne JE, Jabs DA, Peters GB, et al. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol 2005;140:45-51.
12. Ryan SJ, Maumenee AE. Birdshot retinochoroidopathy. Am J Ophthalmol 1980;89:31-45.
13. Rothova A, Suttorp-van SchultenMS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336.
14. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996;114:593-599.
15. Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94:147-158.
16. Priem HA, Kijlstra A, Noens L, et al. HLA typing in birdshot chorioretinopathy. Am J Ophthalmol 1988;105:182-185.
17. LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol 1992;113:33-35.
18. Oh KT, Christmas NJ, Folk JC. Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease. Am J Ophthalmol 2002;133:622-629.
19. Rothova A, Berendschot TT, Probst K, et al. Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology 2004;111:954-959.
20. Ladas JG, Arnold AC, Holland GN. Control of visual symptoms in two men with birdshot retinochoroidopathy using low-dose oral corticosteroid therapy. Am J Ophthalmol 1999;128:116-118.
21. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin. A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996;103:365- 373;discussion 373-374.
22. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.
23. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
24. Lumley T, RK, Ma S. Relative Risk Regression in Medical Research: Models, Contrasts, Estimators, and Algorithms. UW Biostatistics Working Paper Series. 2006. Working Paper 293.
25. Williams R. A note on robust variance estimation for clustercorrelated data. Biometrics 2000;56:645-646.
26. Rabe-Hesketh S. Multilevel and Longitudinal Modeling Using Stata. 2nd ed. College Station, TX: Stata Press; 2008.
27. Rush RB, Goldstein DA, Callanan DG, et al. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol 2011;151:630-636.
28. Thorne JE, Jabs DA, Kedhar SR, et al. Loss of visual field among patients with birdshot chorioretinopathy. Am J Ophthalmol 2008; 145:23-28.
29. Gasch AT, Smith JA, Whitcup SM. Birdshot retinochoroidopathy. Br J Ophthalmol 1999;83:241-249.
30. Chieh JJ, Carlson AN, Jaffe GJ. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Am J Ophthalmol 2008;146:589-594.
31. Panek WC, Holland GN, Lee DA, Christensen RE. Glaucoma in patients with uveitis. Br J Ophthalmol 1990;74: 223-227.
32. Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma 2004;13:461-465.
33. Takahashi T, Ohtani S, Miyata K, et al. A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol 2002; 46:556-562.
34. Ritch R. Pathophysiology of glaucoma in uveitis. Trans Ophthalmol Soc U K 1981;101:321-324.
35. Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol 1997;41:361-394.
36. Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc 1965;24:1274-1278.
37. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17:163-167.
38. Singh IP, Ahmad SI, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004;138:286-287.
39. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
40. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916 e1-7.
41. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res 2009;88:752-759.
42. Malone PE, Herndon LW, Muir KW, Jaffe GJ. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Am J Ophthalmol 2010;149:800-806.